Clinical Trial

Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to assess the effect of multiple doses of the cytochrome P450 (CYP3A4) enzyme inducer carbamazepine (Part A) or the CYP3A4 inhibitor itraconazole (Part B) on the single-dose pharmacokinetics (PK) of AP31969 in healthy participants.
Protocol Amendment History 3 changes
critical Trial completed 2026-05-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-01
critical Recruitment opened 2026-04-24
Trial Details
NCT Number NCT07449390
Lead Sponsor Acesion Pharma
Conditions Healthy Participants
Enrollment 28 participants
Start Date 2026-04-01
Primary Completion 2026-05-09 (estimated)
Study Completion 2026-05-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-22